BTK
Los inhibidores de la tirosina quinasa de Bruton (BTK) son compuestos que específicamente se dirigen e inhiben la BTK, una enzima crucial involucrada en la señalización del receptor de células B y en la regulación de la angiogénesis. La BTK desempeña un papel significativo en la proliferación y supervivencia de las células cancerosas, particularmente en las malignidades hematológicas. Al inhibir la BTK, estos compuestos pueden interrumpir la angiogénesis y el crecimiento tumoral, lo que los convierte en valiosos en la terapia contra el cáncer. En CymitQuimica, ofrecemos una gama de inhibidores de BTK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 174 productos para "BTK".
Filtrar por
Porcentaje de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Precio más bajo
- Precio más alto
- Pureza más baja
- Pureza más alta
- Entrega estimada más rápida
L18I
L18I is a PROTAC (Proteolysis Targeting Chimera) that targets Btk to mitigate inflammation in autoimmune diseases. The components of L18I include the PROTAC target protein ligand IBT6A, the PROTAC linker Propargyl-PEG3-alcohol, and the E3 ubiquitin ligase ligand Lenalidomide-Br. Notably, the active control for the target protein ligand is IBT6A-CO-ethyne, while the conjugate of the E3 ubiquitin ligase ligand with the linker is Lenalidomide-C3-PEG3-N3.Fórmula:C47H51N11O8Forma y color:SolidPeso molecular:897.98BTK inhibitor 17
CAS:BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.Fórmula:C25H24N6O3Pureza:99.57% - 99.88%Forma y color:White SolidPeso molecular:456.4965PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Fórmula:C47H54F2N8O13Forma y color:SolidPeso molecular:976.97SJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Fórmula:C41H45ClN8O7Pureza:98%Forma y color:SolidPeso molecular:797.3FDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Forma y color:Odour SolidIbrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Fórmula:C56H80N12O9SPureza:98%Forma y color:SolidPeso molecular:1097.39IBT6A hydrochloride
CAS:IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.Fórmula:C22H23ClN6OForma y color:SolidPeso molecular:422.911Elsubrutinib
CAS:Elsubrutinib (ABBV-105) is an orally active, selective, and irreversible BTK inhibitor with an IC50 of 0.18 μM for the catalytic domain of BTK.Fórmula:C17H19N3O2Pureza:99.45% - 99.77%Forma y color:White SolidPeso molecular:297.3517GDC-0834
CAS:GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse andFórmula:C33H36N6O3SForma y color:SolidPeso molecular:596.742Zanubrutinib-D5
Zanubrutinib-d5 (BGB-3111-d5) is a deuterium-labeled Zanubrutinib, an orally available Bruton's tyrosine kinase inhibitor for the study of B-cell malignancies.Fórmula:C27H29N5O3Pureza:>99.99%Forma y color:White SolidPeso molecular:476.58NX-5948
CAS:NX-5948 (BTK-IN-24) is a PROTAC-type BTK degrader with anti-inflammatory and anticancer activities, inhibiting B cell activation.Fórmula:C42H54N12O5Pureza:98.29%Forma y color:Yellow SolidPeso molecular:806.96N-piperidine Ibrutinib hydrochloride
CAS:N-piperidine Ibrutinib hydrochloride is a BTK inhibitor that inhibits WT BTK and C481S BTK , which inhibits the growth and proliferation of cancer cells.Fórmula:C22H23ClN6OPureza:98.83%Forma y color:SolidPeso molecular:422.911NRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Fórmula:C43H51N11O6Forma y color:SolidPeso molecular:817.94Poseltinib
CAS:Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.Fórmula:C26H26N6O3Pureza:99.98%Forma y color:Yellow SolidPeso molecular:470.5234-Phenoxyphenylboronic acid
CAS:4-Phenoxyphenylboronic acid inhibits the tyrosine protein kinase BTK, with an IC₅₀ value of 6.09 nM.Fórmula:C12H11BO3Pureza:98.80%Peso molecular:214.025Anti-BTK Antibody (3G585)
Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.Forma y color:Odour LiquidOlmutinib
CAS:Olmutinib is an oral mutant-specific EGFR inhibitor for cancer treatment with potential lower toxicity.Fórmula:C26H26N6O2SPureza:99.14% - 99.63%Forma y color:SolidPeso molecular:486.589Ibrutinib deacryloylpiperidine
CAS:Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.Fórmula:C17H13N5OPureza:99.47%Forma y color:SolidPeso molecular:303.318(Z)-LFM-A13
CAS:(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.Fórmula:C11H8Br2N2O2Pureza:99.88%Forma y color:SolidPeso molecular:360Tuxobertinib
CAS:Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. BDTX-189 exhibits anticancer activity.Fórmula:C29H29ClN6O4Pureza:99.22%Forma y color:SolidPeso molecular:561.031
